European Journal of Rheumatology
Invited Review

Senescence in Osteoarthritis: Overview of Mechanisms and Therapeutics


Beth Israel Deaconess Medical Center, Boston, USA


Harvard Medical School, Boston, USA

Eur J Rheumatol 2024; 11: Supplement S3-S6
DOI: 10.5152/eurjrheum.2023.22077
Read: 1296 Downloads: 1183 Published: 28 November 2023

Osteoarthritis is a morbid and costly condition affecting an increasingly larger segment of the population with a lack of effective treatment options. The pathophysiology of osteoarthritis is poorly understood; cell senescence is deemed to be contributory. Senescence of joint tissues particularly chondrocytes, synoviocytes (fibroblasts), and adipocytes is implicated in the pathogenesis through the production of senescence-associated proteins. Senescence-associated proteins are cytokines, matrix degradation enzymes, and chemokines that contribute to an inflammatory milieu which leads to the propagation of senescence. Senescence-modifying therapies include senolytics which eliminate senescent cells and senomorphics which inhibit the senescence-associated protein production of senescent cells. Treatments being investigated include novel agents as well as agents previously used in other conditions in rheumatology and other fields.

Cite this article as: Surmachevska N, Rubio J. Senescence in osteoarthritis: Overview of mechanisms and therapeutics. Eur J Rheumatol. 2024;11(suppl 1):S3-S6.

EISSN 2148-4279